Browsing by Author "Ravi Shankar Kushwaha"

Now showing 1 - 1 of 1

Protocol and Methods: Role of Levothyroxine on the Progression of Chronic Kidney Disease in Subclinical Hypothyroid Populations (LP‑CKD) – A Multicenter Randomized Controlled Trial
(Wolters Kluwer Medknow Publications, 2023) Narayan Prasad; Shivendra Singh; Vivek Kumar; Manisha Sahay; Arpita Ray Chaudhury; Manas Ranjan Behera; Ravi Shankar Kushwaha; Deependra Yadav; Sonam Gautam; Akhilesh Jaiswal
Introduction: Subclinical hypothyroidism (SCH) is highly prevalent and associated with chronic kidney disease (CKD). However, it is still unanswered whether the restoration of euthyroid status in these patients will be beneficial in retarding a decline in glomerular filtration rate in early CKD patients. We aim to evaluate the efficacy of levothyroxine therapy versus placebo in slowing estimated glomerular filtration rate (eGFR) decline among CKD patients (stage 2–4) with SCH. Methods: This study will be a multicentric, double‑blind, randomized, parallel‑group, placebo‑controlled study. A total of 500 CKD patients, 250 patients in the treatment group and 250 patients in the placebo group, will be randomized. The randomization between the treatment arm and placebo arm will be performed as per the computer‑generated random number table in a 1:1 ratio. The sample size was calculated based on the assumed reduction in eGFR after 1‑year follow‑up in the treatment and placebo groups of 10% and 25%, respectively, at a minimum two‑sided 99% confidence interval and 90% power of the study and considering 20% loss on follow‑up. Each patient will be followed every 3 months for at least 1 year after randomization. Individuals completing 1‑year follow‑up visits will be considered for analysis. The baseline and follow‑up data will be compared between the treatment and placebo groups. The study will evaluate the efficacy and safety of levothyroxine therapy versus placebo in slowing eGFR decline among CKD patients (stage 2‑4) with SCH. The primary endpoint will be the end of follow‑up of the patients, reduction of eGFR by ≥50% from a baseline of that patient, or development of ESKD or death of the patients. The secondary endpoint will be any cardiovascular event or arrhythmia after the institution of the drug. © 2023 Wolters Kluwer Medknow Publications. All rights reserved.